Overview
Portfolio
More
IndieBio
San Francisco, United States
IndieBio backs deep‑tech ventures that apply biology to solve critical challenges for people and the planet. It provides large pre‑seed checks and continues to fund companies through seed and later rounds, focusing on bi...
Portfolio
22+
Employees
50+
Founded
2015
AUM
≈ $306.0M
Investment focus
Stages
Stage agnostic
Industries
Agriculture TechnologyBiotechnologyClean TechnologyHealthcare Technology
Geographic scope
Global
Fund details
Funds
Core Fund
$306.0M
Check sizes
Min: $525.0K
Typical: $525.0K
Sources
IndieBio
IndieBio backs deep‑tech ventures that apply biology to solve critical challenges for people and the planet. It provides large pre‑seed checks and continues to fund companies through seed and later rounds, focusing on biotech, health, climate and agricultural innovations.
Portfolio
22+
Employees
50+
Founded
2015
AUM
≈ $306.0M
Funds
Core Fund · $306.0M
Check Sizes
Min: $525.0K
Typical: $525.0K
Stages
Stage agnostic
Industries
Agriculture TechnologyBiotechnologyClean TechnologyHealthcare Technology
Geographic scope
Global
Sources
Showing 22 of 22 matched portfolio companies
Afynia Laboratories is developing a non-invasive diagnostic tool for endometriosis, targeting the significant issue of chronic pelvic pain and infertility experienced by many women. This technology aims to provide accurate diagnosis without the need for invasive procedures, improving patient outcomes and access to care.
Funding: $5.0M
Rough estimate of the amount of funding raised
Bio-Rad Laboratories
Bio-Rad Laboratories
Funding: $5.0M
Rough estimate of the amount of funding raised
Intelic provides Nexus, an advanced military Command & Control software solution designed for unmanned systems. This platform-agnostic software unifies fragmented defense assets, enabling operators to effectively execute missions across various domains. Nexus integrates mission-focused autonomy to enhance operational speed, coordination, and reliability in contested environments.
Funding: $2.2M
Rough estimate of the amount of funding raised
Keen Venture Partners
Keen Venture Partners
Funding: $2.2M
Rough estimate of the amount of funding raised
Calder Biosciences develops conformationally stabilized prefusion subunit vaccines using its proprietary 3D-Vaxlock™ technology, which creates site-specific, covalent crosslinks in proteins to maintain their most effective 3D structure. This approach aims to provide safe and durable protection against viral infections, including RSV and all strains of influenza, addressing the need for effective vaccines in global health.
Canaery creates biologically enhanced working animals with amplified olfactory abilities to detect explosives, narcotics, pests, and disease biomarkers. Their system combines specialized training, wearable sensors, and adaptive algorithms to deliver real‑time alerts to handlers via portable devices, providing rapid, on‑site screening for security, pest‑control, and healthcare applications.
Funding: $10.4M
Rough estimate of the amount of funding raised
DeepWork Capital
DeepWork Capital
Funding: $10.4M
Rough estimate of the amount of funding raised
Cayuga Biotech develops proprietary biomimetic hemostatic drugs that enhance the body’s natural ability to control bleeding, particularly in non-compressible hemorrhage scenarios where traditional methods fail. The company targets the urgent need for effective treatments in both life-threatening hemorrhage and rare bleeding disorders, addressing the limitations of existing therapies that pose safety risks.
Gozen Bioworks specializes in the development of sustainable biomaterials through advanced bioprocessing techniques and material design. The company addresses the environmental impact of traditional materials by providing eco-friendly alternatives that reduce waste and carbon emissions in various industries.
Founded 2020
Funding: $3.3M
Rough estimate of the amount of funding raised
Funding: $3.3M
Rough estimate of the amount of funding raised
Helex develops genomic medicines utilizing proprietary drug design and lipid nanoparticle delivery platforms to treat genetic kidney diseases. The company focuses on non-viral targeted delivery to the kidney to unlock novel therapeutics for conditions like Autosomal Dominant Polycystic Kidney Disease. Their technology aims to provide safer and more efficient gene editing-based treatments for patients with significant unmet medical needs.
Funding: $3.2M
Rough estimate of the amount of funding raised
Funding: $3.2M
Rough estimate of the amount of funding raised
Hoofprint Biome develops microbiome engineering solutions, specifically probiotics and natural enzymes, to enhance cattle health and yield. Their technology targets the reduction of methane emissions, which currently represent a significant portion of global greenhouse gases. This approach supports sustainable livestock production by improving feed energy efficiency for the animals.
Funding: $4.3M
Rough estimate of the amount of funding raised
AgriZeroNZ
AgriZeroNZ
Funding: $4.3M
Rough estimate of the amount of funding raised
Indee Labs offers Hydropore™, a non-viral microfluidic technology that rapidly delivers small molecules, nucleic acids, and gene-editing complexes to immune cells, producing millions of high-quality cells with minimal impact on viability. This technology addresses the limitations of viral transduction and traditional transfection methods, streamlining the development and manufacturing of engineered cell therapies.
Funding: $5.1M
Rough estimate of the amount of funding raised
Funding: $5.1M
Rough estimate of the amount of funding raised
The startup develops biodegradable molecules that utilize a novel mechanism to sequester lipid peroxides generated by sunlight, pollution, and tobacco smoke, targeting skin aging, sunburn, and skin cancers. Their science-based formulations are produced using green technology, offering effective solutions for anti-aging skincare, sun protection, and over-the-counter anti-acne treatments.
Funding: $410.0K
Rough estimate of the amount of funding raised
IndieBio
IndieBio
Funding: $410.0K
Rough estimate of the amount of funding raised
Lillianah Technologies develops cost-effective carbon removal technology by cultivating specific diatom species in proprietary photobioreactors and releasing them into polluted nearshore marine environments to extract excess nutrients and mitigate ecological issues. This approach targets the removal of over 2 billion tons of CO2e annually, significantly reducing the costs associated with traditional carbon capture methods.
Funding: $625.0K
Rough estimate of the amount of funding raised
Invest Nova Scotia
Invest Nova Scotia
Funding: $625.0K
Rough estimate of the amount of funding raised
MICROTERRA operates a technology platform focused on developing sustainable, high-value ingredients derived from Lemna. The company produces functional, clean-label alternatives that enhance the taste and texture profiles of food and beverage products. This platform addresses industry needs by converting a novel resource into scalable, improved food components.
Minus Materials cultivates carbon-negative limestone from photosynthetic algae, which sequesters atmospheric CO2 during its growth. This bio-renewable limestone serves as a sustainable alternative to quarried limestone in cement production, significantly reducing the carbon emissions associated with traditional cement manufacturing.
Funding: $130.0K
Rough estimate of the amount of funding raised
IndieBioSOSV
IndieBioSOSV
Funding: $130.0K
Rough estimate of the amount of funding raised
Oobli produces plant‑derived sweet proteins via precision fermentation that taste like sugar but are metabolized as protein, eliminating blood‑sugar spikes and gut impacts. Their high‑intensity proteins can replace 60‑90% of sugar in beverages, dairy, confectionery, baked goods and other foods while using minimal land and water. The proteins hold FDA and FEMA GRAS status, enabling food manufacturers to create healthier, climate‑friendly products without compromising taste.
Funding: $18.0M
Rough estimate of the amount of funding raised
Funding: $18.0M
Rough estimate of the amount of funding raised
Prellis utilizes holographic tissue printing technology to create 3D lymph node organoids that replicate human immune responses, enabling the discovery of fully human antibodies with low immunogenicity risk. This approach addresses the challenge of efficiently identifying diverse therapeutic candidates by integrating machine learning with in vitro human biology.
Funding: $79.4M
Rough estimate of the amount of funding raised
Funding: $79.4M
Rough estimate of the amount of funding raised
Puna Bio develops bioinoculants using extremophile microorganisms to enhance crop yields by 10-15% in both fertile and degraded soils. Their technology addresses the challenges of low agricultural productivity and soil degradation while promoting sustainable farming practices.
Funding: $3.7M
Rough estimate of the amount of funding raised
At One VenturesBuilders VC
At One VenturesBuilders VC
Funding: $3.7M
Rough estimate of the amount of funding raised
The startup offers an insight automation platform that utilizes natural language processing to synthesize real-time insights from scientific big data, including articles, clinical trials, and patents. This technology enables researchers to streamline cross-disciplinary discovery in the cloud, significantly accelerating the research process.
Rizlab Health has developed the CytoTracker, a pocket-sized, all-electronic cytometer that provides rapid white blood cell count analysis within minutes using a wireless, AI-driven platform. This technology addresses the need for accessible and affordable blood testing in various settings, including clinical labs, pharmacies, and remote locations.
Funding: $2.3M
Rough estimate of the amount of funding raised
Funding: $2.3M
Rough estimate of the amount of funding raised
Ro operates a telehealth platform that provides online clinics for weight loss, sexual health, hair restoration, and fertility management using clinically proven treatments and prescription medications. The service eliminates the need for insurance and offers free, discreet shipping, making healthcare accessible and convenient for over 2 million members.
The startup develops antineoplastic therapeutics using proprietary scaffold redesign and hopping technology, which integrates mechanism of action and chemical design to target previously undruggable cancer pathways. This approach enables drug researchers to screen trillions of molecules for resistance prediction and antibody redesign, enhancing the durability of therapeutic responses.
Funding: $21.3M
Rough estimate of the amount of funding raised
Funding: $21.3M
Rough estimate of the amount of funding raised
Veloz Bio utilizes molecular farming techniques to produce animal-free alternative proteins, addressing the environmental and ethical concerns associated with traditional animal agriculture. By leveraging plant-based systems for protein synthesis, the company aims to provide sustainable and scalable protein sources for the growing global demand.
Funding: $4.3M
Rough estimate of the amount of funding raised
Funding: $4.3M
Rough estimate of the amount of funding raised
ZymoChem produces BAYSE™, the first fully bio‑based, biodegradable superabsorbent polymer that matches or exceeds the performance of conventional petroleum‑based SAPs used in diapers, feminine hygiene products, and other consumer goods. The material is manufactured at commercial scale from renewable feedstocks, offering manufacturers a drop‑in, high‑absorbency solution that reduces landfill persistence and carbon footprint without a green premium.
+ 2 Other investorsLululemon